Global Assets Advisory LLC Has $2.02 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Global Assets Advisory LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 296.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,285 shares of the company’s stock after purchasing an additional 1,708 shares during the quarter. Eli Lilly and Company accounts for approximately 1.0% of Global Assets Advisory LLC’s holdings, making the stock its 17th biggest holding. Global Assets Advisory LLC’s holdings in Eli Lilly and Company were worth $2,021,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in LLY. Jessup Wealth Management Inc bought a new position in shares of Eli Lilly and Company in the first quarter valued at approximately $303,000. Buckley Wealth Management LLC acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $384,000. Courage Miller Partners LLC bought a new position in Eli Lilly and Company in the 1st quarter valued at $254,000. Fifth Third Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 11.0% in the first quarter. Fifth Third Wealth Advisors LLC now owns 7,536 shares of the company’s stock worth $5,863,000 after purchasing an additional 746 shares in the last quarter. Finally, Indiana Trust & Investment Management CO grew its holdings in shares of Eli Lilly and Company by 5.7% during the first quarter. Indiana Trust & Investment Management CO now owns 16,380 shares of the company’s stock worth $12,743,000 after purchasing an additional 880 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.3 %

LLY opened at $891.66 on Friday. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The firm has a market cap of $847.44 billion, a PE ratio of 131.32, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The firm’s fifty day moving average is $921.12 and its two-hundred day moving average is $860.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Equities research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Citigroup initiated coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target on the stock. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Berenberg Bank upped their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,002.24.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.